688236.SHG Beijing Chunlizhengda Medical Instruments Co Ltd
- Market cap
- CNY 5.27B
- P/E
- 19.2x
- P/B
- 1.64x
- ROE
- 9.1%
- Dividend yield
- 0.36%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 688236.SHG undervalued?
Graham number688236.SHG trades 18.0% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Beijing Chunlizhengda Medical Instruments Co Ltd fundamental analysis
No fundamental analysis for Beijing Chunlizhengda Medical Instruments Co Ltd yet.
Beijing Chunlizhengda Medical Instruments Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Beijing Chunlizhengda Medical Instruments Co Ltd
Beijing Chunlizhengda Medical Instruments Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of surgical implants, instruments, and related products in the People's Republic of China and internationally. The company offers orthopedic medical devices and tissue repair products, including spine, trauma, joint, sports medicine, and bone repair material implants; surgical instrumentation products; platelet-rich plasma preparatio…
Full company profileBeijing Chunlizhengda Medical Instruments Co Ltd financial statements
Beijing Chunlizhengda Medical Instruments Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 208M | 300M | 498M | 855M | 938M | 1.11B | 1.20B | 1.21B | 806M | 1.04B |
| Gross Profit | 159M | 213M | 316M | 585M | 681M | 844M | 900M | 855M | 516M | 1.04B |
| Operating Income | 70.8M | 79.0M | 119M | 274M | 330M | 368M | 329M | 306M | 131M | 302M |
| EBITDA | 79.8M | 85.4M | 127M | 285M | 345M | 384M | 365M | 340M | 169M | 338M |
| Net Income | 63.4M | 68.3M | 106M | 237M | 283M | 322M | 308M | 278M | 125M | 272M |
| EPS | 0.18 | 0.20 | 0.30 | 0.68 | 0.82 | 0.93 | 0.80 | 0.72 | 0.33 | 0.71 |
| Balance Sheet | ||||||||||
| Total Assets | 540M | 634M | 815M | 1.21B | 1.54B | 3.00B | 3.41B | 3.65B | 3.47B | 3.66B |
| Total Liabilities | 59.2M | 95.2M | 187M | 403M | 460M | 531M | 690M | 770M | 644M | -2.99B |
| Shareholders' Equity | 481M | 538M | 628M | 807M | 1.08B | 2.47B | 2.72B | 2.88B | 2.82B | 2.99B |
| Cash & Short-term Investments | 297M | 372M | 415M | 464M | 690M | 1.74B | 1.72B | 2.10B | 1.89B | 2.00B |
| Total Debt | - | - | - | - | 1.85M | 1.23M | 1.31M | 1.75M | 866K | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | 64.9M | 89.8M | 109M | 232M | 261M | 165M | 41.0M | 512M | -1.90M | - |
| Capital Expenditure | 8.36M | 8.98M | 52.1M | 132M | 24.0M | 199M | 24.9M | 33.2M | 49.2M | 59.1M |
| Free Cash Flow | 56.6M | 80.9M | 56.4M | 99.1M | 237M | -34.6M | 16.1M | 478M | -51.1M | 346M |
| Ratios | ||||||||||
| ROE | 13.2% | 12.7% | 16.8% | 29.4% | 26.2% | 13.1% | 11.3% | 9.7% | 4.4% | 9.1% |
| ROA | 11.7% | 10.8% | 13.0% | 19.6% | 18.4% | 10.7% | 9.0% | 7.6% | 3.6% | 7.4% |
| Net Profit Margin | 30.5% | 22.7% | 21.2% | 27.7% | 30.2% | 29.1% | 25.6% | 23.0% | 15.5% | 26.1% |
| Debt to Equity | - | - | - | - | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Beijing Chunlizhengda Medical Instruments Co Ltd dividends
- Dividend yield
- 0.36%
- Forward dividend
- 0.36 CNY
- Payout ratio
- 6.9%
- Ex-dividend date
- Jul 3, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 18.7M | 0.05 | 6.9% |
| 2024 | CNY 171M | 0.45 | 136.4% |
| 2023 | CNY 120M | 0.31 | 43.2% |
| 2022 | CNY 50.0M | 0.13 | 16.2% |
| 2021 | - | - | - |
| 2020 | CNY 10.4M | 0.03 | 3.7% |
| 2019 | CNY 56.8M | 0.16 | 24.0% |
| 2018 | 16.0M | 0.05 | 15.1% |
| 2017 | 10.7M | 0.03 | 15.7% |
| 2016 | 6.09M | 0.02 | 9.6% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Beijing Chunlizhengda Medical Instruments Co Ltd
- Insiders 76.42%
- Institutions 11.01%
- Public & others 12.57%
- Shares outstanding 287M
- Free float 158M
Beijing Chunlizhengda Medical Instruments Co Ltd company profile
- Company name
- Beijing Chunlizhengda Medical Instruments Co Ltd
- Ticker
- 688236.SHG
- ISIN
- CNE1000055K3
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 841
- Fiscal year end
- December
- Address
- No. 10, Xinmi Xi Er Road, Beijing, China
- Phone
- 86 10 8056 1677
- Website
- clzd.com
About Beijing Chunlizhengda Medical Instruments Co Ltd
Beijing Chunlizhengda Medical Instruments Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of surgical implants, instruments, and related products in the People's Republic of China and internationally. The company offers orthopedic medical devices and tissue repair products, including spine, trauma, joint, sports medicine, and bone repair material implants; surgical instrumentation products; platelet-rich plasma preparation kits; and closed wound negative pressure drainage kits. It also provides surgical robots; joint, spinal, sports medicine, trauma, oral care, and endoscopic products; orthopedic power products; and platelet-rich plasma preparation system products, as well as alloy materials and surgical powering equipment. The company exports its products to approximately 68 countries. The company was formerly known as Chunli Limited and changed its name to Beijing Chunlizhengda Medical Instruments Co., Ltd. in September 2010. Beijing Chunlizhengda Medical Instruments Co., Ltd. was incorporated in 1998 and is headquartered in Beijing, China.
Beijing Chunlizhengda Medical Instruments Co Ltd management
7- Ms. Wenling ShiExecutive Chair of the Board · born 1998
- Mr. Chunsheng ShiGeneral Manager · born 1985
- Ms. Shujun YueDeputy GM & Executive Director · born 1971
- Mr. Chunbao ShiChief Engineer & Executive Director · born 1970
- Mr. Feng Bao XieDeputy Chief Engineer, Secretary of the Board & Executive Director · born 1982
- Ms. Hongyue LuCFO & Accounting Supervisor · born 1993
- Mr. Xiwang LiDeputy General Manager · born 1985